Literature DB >> 22262764

Predicting posttransplantation diabetes mellitus by regulatory T-cell phenotype: implications for metabolic intervention to modulate alloreactivity.

Brian G Engelhardt1, Shubhada M Jagasia, James E Crowe, Michelle L Griffith, Bipin N Savani, Adetola A Kassim, Pengcheng Lu, Jörn-Hendrik Weitkamp, Daniel J Moore, Sandra M Yoder, Michael T Rock, Madan Jagasia.   

Abstract

Chronic inflammation and decreased frequency of regulatory T cells (Tregs) in visceral adipose tissue contribute to the propagation of insulin resistance to diabetes mellitus. We tested the hypothesis that new-onset posttransplantation diabetes mellitus (PTDM) is associated with measurable changes in Treg subsets after allogeneic hematopoietic stem cell transplantation (HSCT). PTDM before day 100 and Treg phenotype at engraftment were determined in 36 HSCT recipients without preceding history of diabetes mellitus. Among patients with new-onset PTDM (N = 24), the frequency of circulating CLA(+) (skin-homing) Tregs was decreased (1.53% vs 3.99%; P = .002) and the percentage of α(4)β(7)(+) (gut-homing) Tregs was increased (17.9% vs 10.7%; P = .048). In multivariate analysis, patients with PTDM continued to demonstrate elevated ratios of α(4)β(7)(+) Tregs to CLA(+) Tregs (odds ratio, 18.1; P = .020). PTDM is associated with altered immune regulation after HSCT and could represent a target to modulate alloreactivity.

Entities:  

Mesh:

Year:  2012        PMID: 22262764      PMCID: PMC3311262          DOI: 10.1182/blood-2011-10-384750

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  17 in total

1.  High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT.

Authors:  Katayoun Rezvani; Stephan Mielke; Mojgan Ahmadzadeh; Yasemin Kilical; Bipin N Savani; Josette Zeilah; Keyvan Keyvanfar; Aldemar Montero; Nancy Hensel; Roger Kurlander; A John Barrett
Journal:  Blood       Date:  2006-04-20       Impact factor: 22.113

2.  Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study.

Authors:  K Scott Baker; Kirsten K Ness; Julia Steinberger; Andrea Carter; Liton Francisco; Linda J Burns; Charles Sklar; Stephen Forman; Daniel Weisdorf; James G Gurney; Smita Bhatia
Journal:  Blood       Date:  2006-10-17       Impact factor: 22.113

3.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases.

Authors:  S Sakaguchi; N Sakaguchi; M Asano; M Itoh; M Toda
Journal:  J Immunol       Date:  1995-08-01       Impact factor: 5.422

4.  Hypertension and diabetes mellitus in adult and pediatric survivors of allogeneic hematopoietic cell transplantation.

Authors:  Navneet S Majhail; Tejo R Challa; Daniel A Mulrooney; K Scott Baker; Linda J Burns
Journal:  Biol Blood Marrow Transplant       Date:  2009-09       Impact factor: 5.742

Review 5.  1994 Consensus Conference on Acute GVHD Grading.

Authors:  D Przepiorka; D Weisdorf; P Martin; H G Klingemann; P Beatty; J Hows; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1995-06       Impact factor: 5.483

6.  High prevalence of metabolic syndrome after allogeneic hematopoietic cell transplantation.

Authors:  N S Majhail; M E Flowers; K K Ness; M Jagasia; P A Carpenter; M Arora; S Arai; L Johnston; P J Martin; K S Baker; S J Lee; L J Burns
Journal:  Bone Marrow Transplant       Date:  2008-08-25       Impact factor: 5.483

Review 7.  Leptin in the regulation of immunity, inflammation, and hematopoiesis.

Authors:  G Fantuzzi; R Faggioni
Journal:  J Leukoc Biol       Date:  2000-10       Impact factor: 4.962

8.  A key role of leptin in the control of regulatory T cell proliferation.

Authors:  Veronica De Rosa; Claudio Procaccini; Gaetano Calì; Giuseppe Pirozzi; Silvia Fontana; Serafino Zappacosta; Antonio La Cava; Giuseppe Matarese
Journal:  Immunity       Date:  2007-02       Impact factor: 31.745

9.  Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression.

Authors:  G M Lord; G Matarese; J K Howard; R J Baker; S R Bloom; R I Lechler
Journal:  Nature       Date:  1998-08-27       Impact factor: 49.962

10.  Potential role of regulatory T cells in reversing obesity-linked insulin resistance and diabetic nephropathy.

Authors:  Kathrin Eller; Alexander Kirsch; Anna M Wolf; Sieghart Sopper; Andrea Tagwerker; Ursula Stanzl; Dominik Wolf; Wolfgang Patsch; Alexander R Rosenkranz; Philipp Eller
Journal:  Diabetes       Date:  2011-09-12       Impact factor: 9.461

View more
  8 in total

1.  Human adipose-derived stromal/stem cells induce functional CD4+CD25+FoxP3+CD127- regulatory T cells under low oxygen culture conditions.

Authors:  Trivia P Frazier; James B McLachlan; Jeffrey M Gimble; Hugh A Tucker; Brian G Rowan
Journal:  Stem Cells Dev       Date:  2014-03-11       Impact factor: 3.272

2.  Clinical impact of hyperglycemia on days 0-7 after allogeneic stem cell transplantation.

Authors:  A Kawajiri; S Fuji; Y Tanaka; C Kono; T Hirakawa; T Tanaka; R Ito; Y Inoue; K Okinaka; S Kurosawa; Y Inamoto; S-W Kim; T Yamashita; T Fukuda
Journal:  Bone Marrow Transplant       Date:  2017-03-20       Impact factor: 5.483

3.  New-Onset Post-Transplant Diabetes Mellitus after Allogeneic Hematopoietic Cell Transplant Is Initiated by Insulin Resistance, Not Immunosuppressive Medications.

Authors:  Brian G Engelhardt; Ujjawal Savani; Dae Kwang Jung; Alvin C Powers; Madan Jagasia; Heidi Chen; Jason J Winnick; Robyn A Tamboli; James E Crowe; Naji N Abumrad
Journal:  Biol Blood Marrow Transplant       Date:  2019-02-07       Impact factor: 5.742

Review 4.  How do I manage hyperglycemia/post-transplant diabetes mellitus after allogeneic HSCT.

Authors:  S Fuji; A Rovó; K Ohashi; M Griffith; H Einsele; M Kapp; M Mohty; N S Majhail; B G Engelhardt; A Tichelli; B N Savani
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

Review 5.  Post-haematopoietic cell transplantation outcomes: why ST2 became a 'golden nugget' biomarker.

Authors:  Sophie Paczesny
Journal:  Br J Haematol       Date:  2020-02-10       Impact factor: 6.998

6.  Metabolic Complications Precede Alloreactivity and Are Characterized by Changes in Suppression of Tumorigenicity 2 Signaling.

Authors:  Romany A N Johnpulle; Sophie Paczesny; Dae Kwang Jung; Etienne Daguindau; Madan H Jagasia; Bipin N Savani; Wichai Chinratanalab; Robert F Cornell; Stacey Goodman; John P Greer; Adetola A Kassim; Salyka Sengsayadeth; Michael T Byrne; Brian G Engelhardt
Journal:  Biol Blood Marrow Transplant       Date:  2016-12-21       Impact factor: 5.742

7.  New-onset Post-transplant Diabetes and Therapy in Long-term Survivors After Allogeneic Hematopoietic Stem Cell Transplantation.

Authors:  Vera Dalla Via; JÖrg P Halter; Sabine Gerull; Christian Arranto; AndrÉ Tichelli; Dominik Heim; Jakob R Passweg; Michael Medinger; Nicole Cesana-Nigro
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

Review 8.  Management of endocrino-metabolic dysfunctions after allogeneic hematopoietic stem cell transplantation.

Authors:  Marie-Christine Vantyghem; Jérôme Cornillon; Christine Decanter; Frédérique Defrance; Wassila Karrouz; Clara Leroy; Kristell Le Mapihan; Marie-Anne Couturier; Eva De Berranger; Eric Hermet; Natacha Maillard; Ambroise Marcais; Sylvie Francois; Reza Tabrizi; Ibrahim Yakoub-Agha
Journal:  Orphanet J Rare Dis       Date:  2014-10-29       Impact factor: 4.123

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.